15 May 2002
Endothelin-1 gene polymorphism in the identification of patients at risk for malignant ventricular arrhythmia.
Lýdie Izákovicova Hollá, Milan Kozák, Lýdie Izákovicova Hollá, Lubomír Krivan, Anna Vasků, Milan Sepsi, Semrád Borivoj, Jirí VáchaMed Sci Monit 2002; 8(5): BR164-167 :: ID: 420852
Abstract
BACKGROUND: The endothelins are peptides with vasoconstricting and growth-promotingproperties. Endothelin-1 (ET-1) is known for its direct positive inotropic and chronotropic effects onisolated heart, and for growth effects. The aim of this pilot study was to investigate the frequencydistribution of a common polymorphism of the endothelin (ET-1) gene and its possible relation to thehemodynamic consequences of malignant ventricular arrhythmia in patients with structural heart disease.MATERIAL/METHODS: We studied 26 consecutive patients with malignant ventricular arrhythmia and implantablecardioverter defibrillators (ICD), mean age 62.7 +/- 12.2 years, mean LVEF 0.37 +/- 11. The Taq polymorphismof ET-1 was detected using our original PCR method. The PCR product with a length of 358 bp in its non-mutatedform contains a target sequence for the TaqI restrictive enzyme, while the mutated product loses thiscleavage site. RESULTS: Out of the 26 patients, 9 (34%) had recurrent palpitations and 8 (30.8%) hadsyncopes during their malignant arrhythmic episodes. 19 of the patients were receiving amiodarone afterICD implantation, 7 were not. 15 patients had the (++) and 11 had the (+ -) ET-1 genotype; none had the(- -) genotype. The risk of syncopes was associated with the (++) genotype (p=0.01). Patients with amiodaronehad a significantly higher frequency of the (++) genotype (p=0.011). CONCLUSIONS: All our results suggestedthat the presence of the (++)ET-1 genotype in patients with structural heart disease, severe left ventriculardysfunction, and malignant ventricular arrhythmia put these patients at a higher risk of hemodynamiccollapse during arrhythmic episodes.
Keywords: Arrhythmia, Endothelin-1, Genotype, Hemodynamic Processes, Heterozygote, Homozygote, Pilot Projects, Polymerase Chain Reaction, Polymorphism, Genetic
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952